Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Temitayo Ajayi

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
Clinical Immunology (Orlando, Fla.)|September 12, 2018
Immunogenicity to cerliponase alfa intracerebroventricular enzyme replacement therapy for CLN2 disease: Results from a Phase 1/2 studyAnu Cherukuri, Heather Cahan, Greg de Hart, et al.
The New England Journal of Medicine|April 25, 2018
Study of Intraventricular Cerliponase Alfa for CLN2 DiseaseAngela Schulz, Temitayo Ajayi, Nicola Specchio, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|January 14, 2023
Dysphagia and shortness-of-breath as markers for treatment failure and survival in oropharyngeal cancer after radiationJarey H Wang, Vivian Salama, Lance McCoy, et al.
Clinical and Translational Science|November 17, 2020
Clinical Pharmacokinetics and Pharmacodynamics of Cerliponase Alfa, Enzyme Replacement Therapy for CLN2 Disease by Intracerebroventricular AdministrationAryun Kim, Anita Grover, Kevin Hammon, et al.
Annals of Clinical and Translational Neurology|December 10, 2019
Neurofilament light is a treatment-responsive biomarker in CLN2 diseaseYuanbin Ru, Carley Corado, Russell K Soon, et al.
Microbial Pathogenesis|March 10, 2010
Polymorphisms in the Pseudomonas aeruginosa type III secretion protein, PcrV - implications for anti-PcrV immunotherapySusan V Lynch, Judith L Flanagan, Teiji Sawa, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|April 5, 2011
Ambulatory quantitative waking and sleeping cough assessment in patients with cystic fibrosisEitan Kerem, Michael Wilschanski, Nilsen L Miller, et al.
The Lancet. Child & Adolescent Health|August 19, 2018
Disease characteristics and progression in patients with late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease: an observational cohort studyMiriam Nickel, Alessandro Simonati, David Jacoby, et al.
American Journal of Respiratory and Critical Care Medicine|July 13, 2010
Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosisIsabelle Sermet-Gaudelus, Kris De Boeck, Georges J Casimir, et al.
Blood Advances|February 27, 2023
Pegcetacoplan controls hemolysis in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuriaRaymond Siu Ming Wong, Juan Ramon Navarro-Cabrera, Narcisa Sonia Comia, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
Clinical Immunology (Orlando, Fla.)|September 12, 2018
Immunogenicity to cerliponase alfa intracerebroventricular enzyme replacement therapy for CLN2 disease: Results from a Phase 1/2 studyAnu Cherukuri, Heather Cahan, Greg de Hart, et al.
The New England Journal of Medicine|April 25, 2018
Study of Intraventricular Cerliponase Alfa for CLN2 DiseaseAngela Schulz, Temitayo Ajayi, Nicola Specchio, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|January 14, 2023
Dysphagia and shortness-of-breath as markers for treatment failure and survival in oropharyngeal cancer after radiationJarey H Wang, Vivian Salama, Lance McCoy, et al.
Clinical and Translational Science|November 17, 2020
Clinical Pharmacokinetics and Pharmacodynamics of Cerliponase Alfa, Enzyme Replacement Therapy for CLN2 Disease by Intracerebroventricular AdministrationAryun Kim, Anita Grover, Kevin Hammon, et al.
Annals of Clinical and Translational Neurology|December 10, 2019
Neurofilament light is a treatment-responsive biomarker in CLN2 diseaseYuanbin Ru, Carley Corado, Russell K Soon, et al.
Microbial Pathogenesis|March 10, 2010
Polymorphisms in the Pseudomonas aeruginosa type III secretion protein, PcrV - implications for anti-PcrV immunotherapySusan V Lynch, Judith L Flanagan, Teiji Sawa, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|April 5, 2011
Ambulatory quantitative waking and sleeping cough assessment in patients with cystic fibrosisEitan Kerem, Michael Wilschanski, Nilsen L Miller, et al.
The Lancet. Child & Adolescent Health|August 19, 2018
Disease characteristics and progression in patients with late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease: an observational cohort studyMiriam Nickel, Alessandro Simonati, David Jacoby, et al.
American Journal of Respiratory and Critical Care Medicine|July 13, 2010
Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosisIsabelle Sermet-Gaudelus, Kris De Boeck, Georges J Casimir, et al.
Blood Advances|February 27, 2023
Pegcetacoplan controls hemolysis in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuriaRaymond Siu Ming Wong, Juan Ramon Navarro-Cabrera, Narcisa Sonia Comia, et al.
Pageof 3